Beacon Capital Management LLC (Tennessee)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$849	–	594
2025 Q2	$849	Hold	8	–	–	﹤0.01%	999
2025 Q1	$993	Hold	8	–	–	﹤0.01%	1038
2024 Q4	$985	Hold	8	–	–	﹤0.01%	984
2024 Q3	$891	Hold	8	–	–	﹤0.01%	1120
2024 Q2	$854	Hold	8	–	–	﹤0.01%	966
2024 Q1	$963	Hold	8	–	–	﹤0.01%	962
2023 Q4	$1.03K	Hold	8	–	–	﹤0.01%	873
2023 Q3	$992	Hold	8	–	–	﹤0.01%	924
2023 Q2	$992	Hold	8	–	–	﹤0.01%	924
2023 Q1	$1.17K	Sell	8 -7	-47%	-$1.03K	﹤0.01%	824
2022 Q4	$2.39K	Hold	15	–	–	﹤0.01%	766
2022 Q3	$2K	Sell	15 -1	-6%	-$152	﹤0.01%	732
2022 Q2	$2K	Hold	16	–	–	﹤0.01%	787
2022 Q1	$2K	Buy	+16	New	+$2.32K	﹤0.01%	788

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s JAZZ Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 8 shares — an estimated $849 sold.

Beacon Capital Management LLC (Tennessee) first reported a position in JAZZ in Q1 2022 and held it in 14 quarters. The position peaked at $2.39K in Q4 2022. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 8 Jazz Pharmaceuticals shares in Q3 2025, an estimated $849.
Beacon Capital Management LLC (Tennessee) first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Beacon Capital Management LLC (Tennessee)'s Jazz Pharmaceuticals position peaked at $2.39K in Q4 2022.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.